Watson Pharmaceuticals, Inc.
400 Interpace Parkway
Parsippany
New Jersey
07054
United States
Tel: 862-261-7000 or 800-900-1644 (US Toll Free)
Website: http://www.watson.com/
About Watson Pharmaceuticals, Inc.
About Watson Watson Pharmaceuticals, Inc. is a dynamic organization of more than 6,500 scientists, technicians, sales and marketing, administrative, manufacturing and business professionals working together to achieve our global mission: to help others achieve a better quality of life.Every day, our talented, passionate global teams engage to develop, manufacture, market, sell and distribute generic, brand and biologic pharmaceutical products.
Our Global Success Within our Global Generics business, we are the third leading manufacturer of generic medicines in the U.S. and the 4th leading manufacturer of generic medicines globally. Within our Global Brands team, we are aggressively building a leadership position in Urology and Women’s health in the U.S. and expanding our portfolio internationally. We are also actively engaged in the development of biologics, ensuring Watson is well-positioned for future opportunity.
Impressive Financial Performance Our net revenues continue to climb, increasing 28% to nearly $3.6 billion for full year 2010, compared to net revenue of $2.8 billion for full year 2009. 2011 revenues are forecast to increase to $4.5 billion.
Our Global Businesses We operate and manage our business as three operating segments: Global Generics, Global Brands and Anda Distribution.
Global Generics Our Global Generics team drives Watson’s prominence in the global generic pharmaceutical industry. With more than 160 product families in the U.S. and a significant number of product families in International Markets (Canada, U.K., France and various other markets across Europe, South Africa, Australia, the Pacific Rim and Latin America), our portfolio is among the broadest in the industry. We are focused on bringing to market value-added products that benefit consumers and enhance our market share around the world.
Global Brands Our Global Brands team is leveraging our scientific and manufacturing expertise to develop innovative medicines for key therapeutic categories. We are building our leadership position in Urology and Women’s Health through a portfolio of more than 36 brand products, primarily sold in the U.S. Additionally, our Global Brands team has oversight for Watson’s emergence in biopharmaceuticals – the future of medicine and a significant opportunity for our Company. We are aggressively focused on enhancing the growth of this division through international expansion and key product launches.
Anda Distribution A unique asset within our Global Supply Chain, Anda purchases and distributes generic and select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from more than 200 suppliers (including Watson) to more than 65,000 locations, including 11,000 physician accounts, approximately 17,000 independent pharmacies, and more than 35,000 chain locations. Anda’s skilled tele-sales force and outside national accounts team drive outstanding market coverage and sales volume, making more than 18,000 calls per day. Anda is the 4th largest distributor of generic medicines in the U.S.
Working at Watson Watson offers one of the most exciting, challenging and rewarding work environments in the pharmaceutical industry. We are a dynamic, forward-thinking organization that is currently transforming itself from a U.S.-centric company to one that ranks as a global leader. This dramatic transformation is creating exciting and unique opportunities at all levels across our Company – opportunities that encourage individuals to grow, contribute, innovate and excel.
Our Winning Behaviors Our Winning Behaviors is the foundation of Watson’s powerful global employee culture. By aligning ourselves around a common set of powerful action words - Challenge, Connect, Commit - we sharpen our individual and team focus; more effectively harness the collective talents of our team members; and work together to ensure Watson’s continued global success.
Career Opportunities at Watson At Watson, you will find the ideal environment for applying your professional or technical passion. We welcome new and innovative ideas. And we provide the support and resources that enable you to take your career to new heights.
Learn more about career opportunities at Watson: www.WatsonCareers.com
516 articles about Watson Pharmaceuticals, Inc.
-
Miller Law LLC, Hilliard & Shadowen LLP, Motley Rice LLC, and Cohen Milstein Sellers & Toll PLLC Announce Notice of Class Action for In re Loestrin 24 Fe Antitrust Litigation
10/1/2019
If You Purchased Loestrin 24 Fe, Minastrin 24 Fe and/or Their Generic Equivalent(s) a Class Action Lawsuit May Affect Your Rights
-
Utah’s Salt Lake County is the latest governing body to enter the legal battle against opioid manufacturers, distributors and prescribers. Governments are seeking financial restitution for the funds they have spent on battling addiction to prescription opioid medications.
-
Shire Wins Patent Trial Against Watson Pharmaceuticals, Inc. Concerning LIALDA
3/29/2016
-
Ferring Pharmaceuticals Wins Lysteda Patent Lawsuit Against Watson Pharmaceuticals, Inc., Apotex Corp.
2/4/2014
-
Shire plc Wins Patent Trial Against Watson Pharmaceuticals, Inc. Concerning LIALDA®
5/9/2013
-
Shire plc Settles With Actavis, Watson Pharmaceuticals, Inc. on ADHD Drug
4/25/2013
-
Watson Pharmaceuticals, Inc. is Now Actavis
1/24/2013
-
Watson Pharmaceuticals, Inc. to Acquire Uteron Pharma SA for Up to $305 Million
1/23/2013
-
Watson Pharmaceuticals, Inc. Confirms Opana® ER Patent Challenge
1/23/2013
-
Watson Pharmaceuticals, Inc. To Host 2013 Investor Meeting January 25 in New York
1/11/2013
-
Watson Pharmaceuticals, Inc.'s Generic Lysteda® Receives FDA Approval
1/3/2013
-
Watson Pharmaceuticals, Inc. Confirms Velcade® Patent Challenge
12/28/2012
-
Watson Pharmaceuticals, Inc. to Present at the 31st Annual J.P. Morgan Healthcare Conference
12/21/2012
-
Watson Pharmaceuticals, Inc. at 2013 Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
12/20/2012
-
Watson Pharmaceuticals, Inc. to Present at the 2012 Piper Jaffray Health Care Conference
11/14/2012
-
Watson Pharmaceuticals, Inc.'s Generic Revatio® Receives FDA Approval
11/12/2012
-
Watson Pharmaceuticals, Inc. to Present at the Jefferies and Co. 2012 Global Healthcare Conference
11/7/2012
-
Watson Pharmaceuticals, Inc. to Present at the 2012 Annual Credit Suisse Healthcare Conference
11/7/2012
-
Watson Pharmaceuticals, Inc. CEO Looks to Cut Costs, May Close Some Manufacturing Plants
11/2/2012
-
Watson Pharmaceuticals, Inc. Third Quarter 2012 Non-GAAP Diluted EPS Increases 24% to $1.35; Net Revenue Increases 19% to $1.29 Billion
11/1/2012